GleamWall
中文EN

QGEN QIAGEN N.V.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1015820 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY5.7%
TTM net income YoY408.3%
TTM EPS YoY424.3%
Revenue 3-yr CAGR-0.8%
Net income 3-yr CAGR0.1%

Margins

Gross margin62.2%
Operating margin22.3%
Net margin20.3%
FCF margin21.7%
EBITDA margin31.6%

Returns

ROE11.6%
ROA7.1%
ROIC (approx.)9.1%
Asset turnover0.35x

Leverage & solvency

Liabilities / assets39.9%
Debt / equity0.44x
Current ratio3.90x
Interest coverage14.01x

Cash quality & payout

Operating cash flow / net income1.54x
Accruals ratio-3.8%
Payout ratio12.8%
Capex / revenue9.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$2.09B$1.98B
Cost of revenue$790.50M$1.01B
Gross profit$1.30B$967.35M
R&D expense$187.52M$193.49M
SG&A expense$125.68M$113.43M
Operating income$465.85M$97.71M
Interest expense$33.26M$43.84M
Pretax income$490.26M$121.15M
Income tax$65.39M$37.56M
Net income$424.88M$83.59M
EBITDA$659.60M$300.98M
EPS (basic)1.960.38
EPS (diluted)1.940.37
Dividends declared per share0.25—
Weighted avg. shares (diluted)218.88M224.72M
Balance sheet
Cash & equivalents$839.00M$663.55M
Short-term investments$259.91M$489.44M
Receivables$402.61M$349.28M
Inventory$301.89M$279.26M
Current assets$2.00B$1.96B
PP&E, net$923.95M$753.61M
Goodwill$2.70B$2.43B
Intangibles$386.43M$303.81M
Total assets$6.28B$5.69B
Current liabilities$512.14M$1.04B
Short-term debt$0$551.88M
Long-term debt$1.65B$839.66M
Total debt$1.65B$1.39B
Total liabilities$2.50B$2.12B
Shareholders' equity$3.78B$3.57B
Net debt$815.42M$727.99M
Cash flow statement
Operating cash flow$654.33M$673.55M
Capital expenditure$201.05M$167.17M
Free cash flow$453.28M$506.38M
Investing cash flow-$305.28M-$249.23M
Financing cash flow-$178.98M-$422.90M
Depreciation & amortization$193.75M$203.27M
Stock-based compensation$50.40M$43.63M
Dividends paid$54.24M$0
Share buybacks$280.09M$292.10M

Free plan shows the latest 2 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.